GUT MICROBIOME AS A POTENTIAL BIOMARKER OF ANTI-PD1 THERAPY EFFICACY

• At: AbuDhabi (United Arab Emirates) (2019)
• Type: Poster
• Poster code: POS-HPS-102
• By: MORGADO, Manuel (University of Beira Interior, Health Science Faculty, Portugal)
• Co-author(s): Carolina Lopes: Health Science Faculty, University of Beira Interior, Covilhã, Portugal
  Ema Paulino: Portuguese Pharmaceutical Society, Lisbon, Portugal
  Sandra Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal
  Manuel Morgado: Pharmaceutical Services, University Hospital Center of Cova da Beira, Covilhã, Portugal;Health Science Faculty, University of Beira Interior, Covilhã, Portugal;School of Health Sciences, Polytechnic Institute of Guarda, Guarda, Portugal
  
• Abstract:

  Background

  Anti-PD-1 immunotherapy, a class of immune checkpoint inhibitors (ICI), is effective for advanced melanoma, non-small cell lung cancer and renal cell carcinoma. ICI causes remarkable tumor regression in some patients but not in others. The efficacy of immunotherapy is affected by several factors which include the features of the tumor..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login